GlassScriptPhysician profile
Vedesh K Babu
NPI 1487262267
$1,717.65
in general payments reported to CMS, 2019-2025
13 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $157 · 2023: $380 · 2024: $509 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $538.39 | 2023-2025 | Korlym |
| Amgen INC. | $259.66 | 2024-2025 | Tepezza |
| Mannkind Corporation | $211.92 | 2023-2024 | V-Go |
| Kyowa Kirin, INC. | $124.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.72 | 2021 | |
| Genentech USA, INC. | $102.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $95.82 | 2023 | Lokelma |
| Lilly USA, LLC | $84.31 | 2022-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $74.06 | 2025 | |
| Novo Nordisk INC | $42.52 | 2025 | Ozempic, Rybelsus |
| Insulet Corporation | $28.69 | 2025 | Omnipod |
| Dexcom, INC. | $21.69 | 2025 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $19.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vedesh Babu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.